PDB119 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN

The objective was to understand treatment patterns and persistence, and associated costs among type 2 diabetes (T2DM) patients starting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in routine clinical practice in Spain. A retrospective observational study was conducted based on medical records from the BIG-PAC database (Spain). T2DM patients ≥18 years initiating a new treatment with the most widely used GLP-1 RAs, either once-weekly exenatide-QW, once-weekly dulaglutide, or once-daily liraglutide (index therapy) between 01/11/2015 and 30/06/2017 (index date) were included. Patients were considered persistent until evidence of discontinuation (defined as the occurrence of a gap in a series of successive dispensations for the patient’s initial treatment ≥60 day’s duration) or switch. The proportion of persistent patients over time was estimated using Kaplan-Meier survival curves. Change in HbA1c and costs of T2DM related health resource utilization including medications, from index date until 12-months of treatment, were evaluated. All analyses were descriptive. 1,402 patients were included (438 exenatide-QW, 492 dulaglutide, 472 liraglutide), 52.8% were male, with mean (SD) age 62.3 (10.7) years, HbA1c 8.1% (1.2) and body mass index 35.5 (3.2) at index date. At 12 months, persistence (95% CI) to index treatment was 56.8% (52.2% - 61.4%) with exenatide-QW, 69.7% (65.6% - 73.8%) with dulaglutide, and 58.3% (53.9% - 62.7%) with liraglutide. Average reduction in HbA1c at 12-months was -0.5% for patients initiating exenatide-QW , -0.7% for dulaglutide, and -0.5% for liraglutide. The total annual average T2DM related cost (SD) was 4,418.4 (2,382.6) € with exenatide-QW, 4,072.1 (1,946.0) € with dulaglutide, and 4,382.7 (2,389.2) € with liraglutide. The proportion of patients persistent at one year was highest among dulaglutide patients and lowest among exenatide-QW patients. The total annual average T2DM related costs were lowest for dulaglutide and highest for exenatide-QW.